CASP10 Gene Autoimmune Lymphoproliferative Syndrome Type 2A Genetic Test in UAE | 2800 AED | DHA Licensed

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Executive Summary & Core Metrics

This advanced Next‑Generation Sequencing test comprehensively analyzes the CASP10 gene for pathogenic variants that cause Autoimmune Lymphoproliferative Syndrome type 2A (ALPS‑2A), a rare inherited immune dysregulation disorder. The result empowers dermatologists, rheumatologists, and clinical immunologists to confirm a molecular diagnosis, predict disease trajectory, and tailor immunosuppressive or targeted therapies with high precision. The test is conducted at our DHA‑licensed facility (License No. 1143) in Dubai Healthcare City, ensuring full compliance with UAE genetic testing regulations.

Test Overview & Methodology

The CASP10 gene test employs high‑depth Next‑Generation Sequencing (NGS) with orthogonal Sanger confirmation to detect single‑nucleotide variants and small insertions or deletions across all coding exons and flanking intronic regions. This dual‑method approach achieves 99.9% analytical sensitivity for pathogenic variants in the CASP10 gene, which encodes caspase‑10, a key protease in the extrinsic apoptotic pathway. Dysfunction of this protein leads to uncontrolled lymphocyte survival and the clinical manifestations of ALPS‑2A. Our methodology exceeds panel‑only approaches that may miss deep intronic or complex variants.

Feature	Our Test (DHA‑Licensed)	Closest Alternative
Precision	99.9% analytical sensitivity for CASP10 coding regions	May miss deep intronic variants; panel‑only approach
Method	High‑depth NGS with Sanger confirmation	Standard NGS; often without orthogonal validation
Speed	3–4 Weeks	4–8 Weeks

Physician Insight & Safety Protocols

“A positive CASP10 mutation alone does not seal the diagnosis – it must be interpreted alongside your full clinical picture, family history, and laboratory markers. Our dedicated team ensures that every report is reviewed by a DHA‑licensed specialist who can guide you through the next steps. This test provides clarity, not fear; never stop any prescribed medication without first discussing the result with your treating physician.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Medication Advisory

Do not discontinue or alter any prescribed medication without consulting your treating physician. Genetic findings may refine therapy options but never replace clinical judgment. Always discuss your results with your specialist before making treatment changes.

Exclusion Criteria & Emergency Red Flags

Who Should Not Undergo This Test

Minors (below 18) without legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Acute febrile illness or active infection that may compromise sample quality.
Severe bleeding diathesis unmanaged (relative contraindication).
Pregnancy – genetic counseling mandatory before testing.

Seek Immediate Emergency Care If

Rapidly enlarging lymph nodes or spleen (early satiety, left upper pain).
Sudden pallor, jaundice, or dark urine (autoimmune hemolytic crisis).
Severe bruising, petechiae, or mucosal bleeding (thrombocytopenia).
High fever with unresponsiveness to antipyretics.

Patient FAQ & Clinical Guidance

1. What is the CASP10 genetic test and why is it important?

This NGS test identifies CASP10 gene mutations responsible for Autoimmune Lymphoproliferative Syndrome type 2A, enabling precise diagnosis and personalized therapy. It is clinically indicated when a patient presents with unexplained chronic lymphadenopathy, splenomegaly, autoimmune cytopenias, or family history of ALPS. Confirming a pathogenic variant helps differentiate ALPS from other immune deficiencies and directs targeted management, including potential use of sirolimus or other immunomodulators. A mandatory genetic counseling session is required before testing to draw a detailed pedigree and review family history.

2. How is the sample collected and what is the turnaround time?

You provide a blood sample via a home‑visit VIP phlebotomist, and receive your genetic results within 3 to 4 weeks. Sample collection is handled through our temperature‑controlled cold‑chain logistics, available daily from 8 AM to 11 PM. The collected peripheral whole blood is transported directly to our DHA‑licensed facility with full temperature monitoring, ensuring optimal DNA integrity for high‑depth sequencing. No fasting is required; continue all regular medications unless otherwise instructed by the genetic counselor. For children and adolescents, a parent or legal guardian must be present and provide written consent.

3. Is this test approved by UAE health authorities and covered by insurance?

Yes, this is performed in a DHA‑licensed facility (License No. 1143), fully compliant with UAE genetic testing laws, and insurance verification is available. Under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, all genetic data is strictly confidential and processed within the country. We hold ISO 9001:2015 certification. Most major health insurers in the UAE reimburse ALPS genetic testing when pre‑authorized; our team handles direct billing verification and can assist you in obtaining approval via WhatsApp at +971 54 548 8731.

UAE Regulatory & Data Privacy Adherence

Your genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genomic information is encrypted, stored on local servers, and never shared without your explicit written consent. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility operates under DHA Facility License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. We maintain strict access controls and audit trails to ensure complete confidentiality of your medical records.

Clinical & Logistical Metadata

Test Name	CASP10 Gene Autoimmune Lymphoproliferative Syndrome Type 2A Genetic Test
Price (AED)	2800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection)
Methodology Used	High‑Depth Next‑Generation Sequencing (NGS) with Sanger Confirmation
ICD-10-CM Code	D47.29 (Autoimmune lymphoproliferative syndrome)
LOINC Code	94085-1 (CASP10 gene targeted mutation analysis)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE